EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of Risdiplam Treatment in Adult Patients With Spinal Muscular Atrophy Type IIb–III

Daniel Apolinar García Estévez

Revista de Neurología · 26.01.2026 · 81 (1)

DOI: 10.31083/rn44408 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista de Neurología, online erschienen am 26.01.2026. Verfasst von Daniel Apolinar García Estévez. Beteiligte Einrichtung: Neurology Service, Ourense University Hospital, 32005 Ourense, Spain. Hauptthemen laut MEDLINE: Spinal Muscular Atrophies of Childhood, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Risdiplam is a pharmacological agent developed for the treatment of spinal muscular atrophy (SMA) associated with 5q deletion, with the therapeutic objective of increasing the concentration of the survival motor neuron 2 protein. Most clinical trials and real-world studies have focused on pediatric and young adult populations. Our aim was to assess the effectiveness of risdiplam treatment in adult patients with SMA type IIb and III.

Methods

We studied 8 adult patients with SMA (3 females/5 males). Patient functionality was assessed using the Egen Klassifikation version 2 (EK2) scale, upper limb function with the 9-hole peg test (9HPT, seconds), and respiratory function with peak flow (L/min) and sniff nasal inspiratory pressure (SNIP, cmH2O). Plasma levels of neurofilament light chain (NFL, pg/mL) and glial fibrillary acidic protein (GFAP, pg/mL) were also measured. Patients were evaluated at baseline, and after 6 and 12 months of treatment.

Results

The median age was 55 years (range: 41–66). At 12 months, EK2 scores showed a trend toward improvement in swallowing [item 16] (p = 0.06), peak flow increased significantly (244 ± 112 vs. 259 ± 124 L/min, p = 0.036), and there was a trend toward decreased NFL levels (11.4 ± 4.9 vs. 9.4 ± 2.7 pg/mL, p = 0.093). Both NFL and GFAP concentrations were negatively correlated with peak flow and SNIP values.

Conclusions

In our series, treatment with risdiplam may stabilize adult patients with type IIb–III SMA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal Muscular Atrophies of ChildhoodPyrimidinesHumansFemaleAdultMaleMiddle AgedTreatment OutcomeAgedGlial Fibrillary Acidic ProteinNeurofilament ProteinsAzo Compounds

Stichwörter der Autor:innen

biomarkersglial fibrillary acidic proteinmotor neurone diseaseneurofilamentsrisdiplamspinal muscular atrophy

Substanzen

RisdiplamPyrimidinesGlial Fibrillary Acidic ProteinNeurofilament ProteinsAzo Compounds

Autor:innen und Institutionen

  • Neurology Service, Ourense University Hospital, 32005 Ourense, Spain.
  • Clinical Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Alvaro Cunqueiro Hospital, 36123 Vigo, Spain.

Förderung

  • Roche

Zitieren

APA

García Estévez, D. A. (2026). Effectiveness of Risdiplam Treatment in Adult Patients With Spinal Muscular Atrophy Type IIb–III. Revista de Neurología, 81(1). https://doi.org/10.31083/rn44408

Vancouver

García Estévez DA. Effectiveness of Risdiplam Treatment in Adult Patients With Spinal Muscular Atrophy Type IIb–III. Revista de Neurología. 2026;81(1). doi:10.31083/rn44408

BibTeX
@article{GarcaEstvez2026,
  author = {García Estévez, Daniel Apolinar},
  title = {Effectiveness of Risdiplam Treatment in Adult Patients With Spinal Muscular Atrophy Type IIb–III},
  journal = {Revista de Neurología},
  year = {2026},
  volume = {81},
  number = {1},
  doi = {10.31083/rn44408}
}
Kostenlos starten →